Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion deal, accelerating efforts to broaden its respiratory portfolio as it prepares for the loss of exclusivity on... ...